Posted in Celgene, Glaxosmithkline, GSK, J&J, Johnson and Johnson, Marketing, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Top News, Training Needs, tagged revlimid, Velcade on November 30, 2009 |
Welcome back from Thanksgiving holiday! Can’t believe it’s already December…
This will be the only Impactiviti Daily this week, as I am heading down to South Carolina for the graduation of my #2 son (David) from Marine boot camp.
Layoffs. Sanofi reps are apparently getting the news this week. Ugh.
Will Celgene‘s Revlimid take off even faster? – Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Johnson & Johnson’s intravenous medicine, Velcade.
Court to Glaxo reps seeking overtime pay: No. FDA to Novartis on seasonal flu shot: Yes.
Speaker Training. The Impactiviti network of providers has what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Mystic the Marketing Lab gives her first interview. On canine branding.
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
Read Full Post »
Posted in Boehringer Ingelheim, News, Pfizer, Pharma, Pharma News, Pharmaceutical, Sales training, Statins, Top News, tagged Genzyme, gerd, prevnar, revatio, vivus on November 20, 2009 |
Posted in Abbott, BMS, Boehringer Ingelheim, Bristol Myers, J&J, Merck, Novartis, Pharma, Pharma News, Pharmaceutical, Top News, tagged flibanserin, h1n1, Mead Johnson, Zetia on November 17, 2009 |
Whew! The back-to-back conference marathon is now over, and we can get back to our regular pharma news reporting. Here’s what’s up today…
Everyone’s talking about the Zetia/Niaspan study – its results, its significance, its limitations. Bottom line – I can’t see how this can be good for Merck. More here. And Jim Edwards analyzes the damage control spin effort here.
Always a headline topic: female sexual desire treatments. The more you read about this drug (experimental ‘flibanserin’ from Boehringer-Ingelheim), however, the more you wonder if the purported effect will be worth the expense and the side effects.
BMS pushing Mead-Johnson out of the nest. It is amazing to me how drug companies cycle through periods where they diversify, then spin divisions off…
Novartis: half a dose of H1N1 vaccine may be enough. Now that’s how to increase vaccine supply!
If you’re going to blow the whistle, I guess it’s important to get on to the field of play! Whistleblower lawsuit against J&J dismissed.
Leadership – talent selection. How is your organization choosing leaders? Impactiviti’s provider network has proven, best-in-class talent selection/management solutions. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Is this drug a frog, or a prince? I dunno, but I like the picture…!
JUST FOR FUN
Read Full Post »